No Data
China Includes Kanion Pharma's Anti-Constipation Granules in Insurance Drug Catalog
Jiangsu Kanion Pharmaceutical (600557.SH): Some pharmaceutical products of the company have been included in the "National Medical Insurance Directory".
GeLonghui Nov. 29th | jiangsu kanion pharmaceutical (600557.SH) announced that the National Medical Insurance Administration and the Ministry of Human Resources and Social Security have issued the "Notice on Printing and Distributing <National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2024)>. According to the notice, Jiangsu Kanion Pharmaceutical Co., Ltd.'s exclusive product Jichuan Decoction Granules was included in the <National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2024)> for the first time through negotiation. The company's products Jin Gu Zhi Tong Pain Relief Gel (exclusive product) and Linggui Shugan Granules were adjusted from the negotiation directory to the national medical insurance regular directory this time; Pirfenidone
China Approves Jiangsu Kanion Pharmaceutical's Clinical Trial for Psoriasis Cream
Jiangsu Kanion Pharmaceutical (600557.SH) has received the clinical trial approval notice for KYHY2302 cream.
Jiangsu Kanion Pharmaceutical (600557.SH) announced that the company recently received a Class 1 new chemical drug issued by the National Medical Products Administration.
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Low P/E No Reason For Excitement
US FDA Approves Kanion Pharma's Clinical Trial for Psoriasis Injection
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
No Data
